About: SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
Creator	Li, Jing Zhang, Jie Chen, Long Luo, Chunxia Sun, Chunyun Xie, Liangzhi Yang, Ji Yang, Jiahui Zhang, Yanjing
Source	BioRxiv; MedRxiv
abstract	SARS-CoV-2 and SARS-CoV share a common human receptor ACE2. Protein-protein interaction structure modeling indicates that spike-RBD of the two viruses also has similar overall binding conformation and binding free energy to ACE2. In vitro assays using recombinant ACE2 proteins and ACE2 expressing cells confirmed the two coronaviruses’ similar binding affinities to ACE2. The above studies provide experimental supporting evidences and possible explanation for the high transmissibility observed in the SARS-CoV-2 outbreak. Potent ACE2-blocking SARS-CoV neutralizing antibodies showed limited cross-binding and neutralizing activities to SARS-CoV-2. ACE2-non-blocking SARS-CoV RBD antibodies, though with weaker neutralizing activities against SARS-CoV, showed positive cross-neutralizing activities to SARS-CoV-2 with an unknown mechanism. These findings suggest a trade-off between the efficacy and spectrum for therapeutic antibodies to different coronaviruses, and hence highlight the possibilities and challenges in developing broadly protecting antibodies and vaccines against SARS-CoV-2 and its future mutants.
has issue date	2020-02-20(xsd:dateTime)
bibo:doi	10.1101/2020.02.16.951723
has license	biorxiv
sha1sum (hex)	724989927913f3cfd77275ecfc6e7d762502e13a
schema:url	https://doi.org/10.1101/2020.02.16.951723
resource representing a document's title	SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
schema:publication	bioRxiv
resource representing a document's body	covid:724989927913f3cfd77275ecfc6e7d762502e13a#body_text
is schema:about of	named entity 'mechanism' named entity 'neutralizing' named entity 'RBD' named entity 'SPECTRUM' named entity 'MODELING' named entity 'blocking' named entity 'experimental' named entity 'studies' named entity 'binding' named entity 'activities' named entity 'antibodies' named entity 'neutralizing antibodies' named entity 'proteins' named entity 'ACE2' named entity 'coronaviruses' named entity 'highlight' named entity 'possibilities' named entity 'high' named entity 'Receptor' named entity 'receptor' named entity 'coronaviruses' named entity 'viruses' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'binding affinities' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'Vaccine' named entity 'Receptor Binding' named entity 'Potential Implications' named entity 'SARS-CoV' named entity 'receptor' named entity 'RBD' named entity 'conserved regions' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'amino acid sequence homology' named entity 'ACE2' named entity 'viruses' named entity 'microplate reader' named entity 'cross-reactive' named entity 'SARS-CoV-2' named entity 'PSV' named entity 'recombinant' named entity 'coronaviruses' named entity 'neutralizing antibody' named entity 'protein' named entity 'protein' named entity 'protein' named entity 'data processing' named entity 'binding affinities' named entity 'SARS-CoV' named entity 'recombinant' named entity 'ACE2' named entity 'ACE2' named entity '293T cells' named entity 'Neutralizing antibodies' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'HIV-1' named entity 'transmissibility' named entity 'RBD' named entity 'epitopes' named entity 'PSV' named entity 'SARS-CoV' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'Antibodies' named entity 'SARS-CoV' named entity 'transfection' named entity 'neutralizing antibodies' named entity 'SARS-CoV' named entity 'neutralizing antibodies' named entity 'SARS-CoV-2' named entity 'life-threatening diseases'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software